Medicines for Malaria Venture Trials

47 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Krintafel (tafenoquine) / 60° Pharma

ACTRN12622000272796p: Evaluation of weekly tafenoquine antimalarial prophylaxis in Vietnam People’s Army personnel in South Sudan

Not yet recruiting

Australian Defence Force Malaria and Infectious Disease Institute, Australian Defence Force Malaria and Infectious Disease Institute

Malaria

ACTRN12622000272796: Evaluation of weekly tafenoquine antimalarial prophylaxis in Vietnam People’s Army personnel in South Sudan

Withdrawn

Australian Defence Force Malaria and Infectious Disease Institute, Australian Defence Force Malaria and Infectious Disease Institute

Malaria

TQ, NCT05203744: Escalating Monthly Doses of Tafenoquine in Healthy Volunteers

Not yet recruiting

200

RoW

Tafenoquine prophylaxis, TQ

Naval Medical Research Center, Naval Medical Research Unit TWO (NAMRU-2), Australian Defence Force Malaria and Infectious Disease Institute (ADF MIDI), The 108 Military Central Hospital, Naval Environmental Preventive Medicine Unit TWO (NEPMU-2)

Prophylaxis

12/22

VET, NCT06575647: Vivax Elimination With Tafenoquine () Study

Active, not recruiting

1000

RoW

Tafenoquine

Shoklo Malaria Research Unit, Mahidol Oxford Tropical Medicine Research Unit

Malaria, Malaria, Vivax, Plasmodium Vivax, Plasmodium Vivax Malaria

12/25

ACTQ, NCT05788094: ACT vs CQ With Tafenoquine for P. Vivax Mono-infection

Recruiting

606

RoW

Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose), Chloroquine plus Tafenoquine (450 mg adult dose), Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)

Shoklo Malaria Research Unit, Mahidol Oxford Tropical Medicine Research Unit, University of Oxford

Malaria, Malaria, Vivax, Plasmodium Vivax Malaria

02/26

08/26

TBM, NCT04984759: Tafenoquine and Primaquine in Colostrum and Breast Milk

Withdrawn

RoW

Primaquine, Primaquine GPO®, Tafenoquine, Kodatef

University of Oxford, Mahidol Oxford Tropical Medicine Research Unit

Healthy Lactating Women

06/25

NCT07052162: Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children

Not yet recruiting

RoW

Single dose tafenoquine (10 mg/kg) given with water, TQ, Tafenoquine succinate, Kodatef, Single dose tafenoquine (10 mg/kg) given with fat

Curtin University, Papua New Guinea Institute of Medical Research, The University of Western Australia

Pharmacokinetics of Tafenoquine

12/25

SEADOT, NCT04704999: Southeast Asia Dose Optimization of Tafenoquine

Recruiting

700

RoW

Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg

University of Oxford, PATH

Plasmodium Vivax Malaria

10/27

02/28

EFFORT, NCT04411836: Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine

Completed

960

RoW

Tafenoquine, Primaquine, Primaquine 7 days

Menzies School of Health Research, University of Melbourne, National Centre for Parasitology, Entomology and Malaria Control, Cambodia, Mahidol Oxford Tropical Medicine Research Unit, Ethiopian Public Health Institute, Universitas Sumatera Utara, Arba Minch University, Aga Khan University

Vivax Malaria, Plasmodium Vivax, Malaria, Vivax, Malaria Relapse

09/24

TADORE, NCT06148792: A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria

Recruiting

1090

RoW

Tafenoquine, Primaquine

Menzies School of Health Research, University of Melbourne, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Arba Minch University, Addis Ababa University, Papuan Community Health and Development Foundation, Indonesia, Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Indonesia, Curtin University, Papua New Guinea Institute of Medical Research

Vivax Malaria

03/27

NCT06666491: An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

Recruiting

300

RoW

Tafenoquine, Primaquine, Chloroquine

GlaxoSmithKline

Malaria, Vivax

07/26

NCT05947812: A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression

Not yet recruiting

148

Tafenoquine Oral Tablet, KODATEF™, Arakoda, Placebo

60P Australia Pty Ltd

COVID 19 Disease, Mild to Moderate COVID 19 Disease, SARS-CoV-2, Infectious Disease, Severe Acute Respiratory Syndrome Coronavirus 2

04/24

TQ-BA-2024-1, NCT06207370: Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis

Recruiting

Tafenoquine, Placebo

60 Degrees Pharmaceuticals LLC

Babesiosis

03/25

07/25

TQ-BA-2024-3, NCT06656351: Phase 2 Open Label Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

Not yet recruiting

Tafenoquine 100mg

60 Degrees Pharmaceuticals LLC

Chronic Babesiosis

02/27

09/27

ACTRN12620000995976: Blood stage antimalarial activity of tafenoquine in healthy subjects infected with Plasmodium falciparum

Completed

QIMR Berghofer Medical Research Institute, Bill and Melinda Gates Foundation

Malaria

NCT06478641: Expanded Use in Persistent (B. Microti) Babesiosis

Available

N/A

Tafenoquine

60 Degrees Pharmaceuticals LLC

Persistent Babesiosis

Trust, NCT05096702: Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil

Active, not recruiting

N/A

16000

RoW

Tafenoquine, Kozenis, Primaquine

Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Centro de Pesquisa em Medicina Tropical, Medicines for Malaria Venture, Ministry of Health, Brazil, Secretária Municipal de Saúde de Manaus, Secretária Estadual de Saúde do Amazonas

Malaria, Vivax, G6PD Deficiency

08/22

09/23

ARCTIC, NCT05753150: Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand

Completed

N/A

187

RoW

Tafenoquine, Kozenis, Primaquine

Dr. Prayuth Sudathip, Medicines for Malaria Venture

Malaria, Vivax, G6PD Deficiency

08/23

10/23

NCT05361486: Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru

Recruiting

N/A

RoW

Training on revised algorithm, Enhancing Pharmacovigilance, Supervision of malaria services in selected facilities., G6PD testing, Tafenoquine, Kozenis, Primaquine, Follow Up Visit at Day 3 [+2 days] after treatment start

Medicines for Malaria Venture, Universidad Peruana Cayetano Heredia, UNITAID, ICON plc

Malaria, Vivax

10/24

CUREMA, NCT05540470: Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield

Recruiting

N/A

5000

RoW

PART, chloroquine, primaquine, tafenoquine, module A, Malakit, module B, CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS, ORPAL 3 - 4, QUALITATIVE STUDY

Centre Hospitalier de Cayenne, Oswaldo Cruz Foundation, Foundation for Scientific Research Suriname (SWOS) Paramaribo, Suriname

Malaria, Vivax

12/24

12/25

cabamiquine (M5717) / EMD Serono

NCT05689047: Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)

Completed

RoW

M5717 330 mg, M5717 500 mg, M5717 660 mg, Pyronaridine 360 mg, Pyronaridine 540 mg, Pyronaridine 720 mg, Pyronaridine-artesunate (Pyramax) 360 mg/120 mg, Pyronaridine- artesunate (Pyramax) 540 mg/180 mg, Pyronaridine-artesunate (Pyramax) 720 mg/240 mg

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Acute Malaria

05/24

NCT05974267: Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

Completed

192

RoW

M5717 60 mg, Pyronaridine, Pyronaridine tetraphosphate, Atovaquone-Proguanil, M5717 200 mg, M5717 660mg

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Malaria Infection

12/24

Pyramax (artesunate/pyronaridine) / Medicines for Malaria Venture, Shin Poong Pharma

ACTRN12622001407785: Efficacy and safety of pyronaridine-artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in Gia Lai province, Viet Nam in 2022.

Not yet recruiting

World Health Organization, World Health Organization, National Malaria control program

Patients infected with plasmodium falciparum.

ACTRN12618001348246: Evaluation of the efficacy and safety of the drugs Pyronaridine-Artesunate (Pyramax™) and Primaquine to treat uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Salavanh province, Lao PDR

Not yet recruiting

120

Ministry of Health, World Health Oranization , Ministry of Health

Malaria

ACTRN12621001743853: Efficacy and safety of pyronaridine-artesunate for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine for the treatment of uncomplicated Plasmodium vivax malaria in Binh Phuoc, Gia Lai and Phu Yen provinces, Viet Nam in 2021.

Recruiting

World Health Organization, World Health Organization, National Malaria control program

Patients infected Plasmodium falciparum , Patients infected Plasmodium vivax

CHIMIO2, NCT04778813: Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso

Not yet recruiting

1050

RoW

Artemether-lumefantrine, Dihydroartemisinin pyperaquin, Artesunate Pyronaridine

Centre national de recherche et de formation sur le paludisme, Programme national de lutte contre le paludisme (PNLP), Burkina Faso, Unité de recherche clinique de Nanoro (URCN), USAID/IMPACT Malaria

Malaria, Burkina Faso

12/21

06/22

APACT, NCT03726593: Drug Combinations of Atovaquone-Proguanil (AP) With ACT

Recruiting

252

RoW

Artesunate and Pyronaridine, Atovaquone Proguanil and Artesunate Pyronaridine, Atovaquone Proguanil and Artesunate Mefloquine

Armed Forces Research Institute of Medical Sciences, Thailand, National Center for Parasitology, Entomology, and Malaria Control (CNM), Naval Medical Research Unit-2 (NAMRU-2)

Plasmodium Falciparum Malaria (Drug Resistant)

08/22

12/22

MALCOV, NCT04695197: Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso

Completed

143

RoW

Artemether-lumefantrine (AL), Coartem, Pyronaridine-artesunate (PA), Pyramax

Liverpool School of Tropical Medicine, London School of Hygiene and Tropical Medicine, Kenya Medical Research Institute, Groupe de Recherche Action en Sante, Centres for Disease Control and Prevention, Kenya., Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention

Covid-19, Malaria

11/22

02/24

NCT05084911: The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)

Completed

1807

Europe, RoW

Pyramax, Placebo

Shin Poong Pharmaceutical Co. Ltd.

COVID-19

03/23

SAFIRE, NCT06962319: Safety of Antimalarials in the FIRst trimEster

Not yet recruiting

1510

RoW

dihydroartemisinin-piperaquine (DP), Pyronaridine-artesunate (PA), Artemether-lumefantrine

Liverpool School of Tropical Medicine, Malaria Research and Training Center, Mali International Center of Excellence in Research, University of Sciences, Techniques, and Technologies of Bamako, Mali, KEMRI Centre for Global Health Research (CGHR), Kisumu, Kenya, Clinical Research Unit of Nanoro (CRUN), Institut de Recherche en Sciences de la Santé, Medicines for Malaria Venture (co-sponsor), US Centers for Disease Control and Prevention (CDC), Division of Parasitic Diseases & Malaria

Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)

08/28

08/29

ACTRN12622000638730: Monitoring and evaluation of the efficacy and safety of Artesunate-Mefloquine (ASMQ) and Artesunate-Pyronaridine (ASP) for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Cambodia

Terminated

2/3

120

Ministry of Health, World Health Organization

Patients with Plasmodium falciparum infection, Patients with Plasmodium vivax infection

PROVIDENCE, NCT04701606: The Safety and Efficacy of Pyronaridine-artesunate (PyramaxÂ® or ArtecomÂ®)in COVID-19 Patients

Recruiting

2/3

402

RoW

ArtecomÂ® (pyronaridine-artesunate), PyramaxÂ® (pyronaridine-artesunate), Placebo

Shin Poong Pharmaceutical Co. Ltd.

Covid19

04/22

NCT05441410: Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults

Not yet recruiting

1/2

Pyronaridine Tetraphosphate, Artesunate Drug Combination, Pyramax, PfSPZ Challenge (NF54), MVA ME-TRAP, ChAd63 ME-TRAP, Sodium chloride (NaCl) 0.9%, Placebo: Saline

University Hospital Tuebingen, Sanaria Inc., University of Oxford

Malaria

06/26

NCT05929157: A Crossover Bioavailability Clinical Trial of Parenteral Pyronaridine and Artesunate

Not yet recruiting

1/2

RoW

artesunate-pyronaridine

Centre de Recherche Médicale de Lambaréné, Institute of Tropical Medicine, University of Tuebingen

Severe Malarial Treatment

12/24

06/25

ACTRN12618001621202: Therapeutic efficacy of pyronaridine-artesunate for Plasmodium vivax in Myanmar

Not yet recruiting

N/A

140

Ministry of Health and Sports, WHO/GMS (World Health Organization/Greater Mekong Subregion)

malaria

ACTRN12618001620213: Therapeutic efficacy studies of pyronaridine-artesunate combination for the treatment of uncomplicated Plasmodium falciparum malaria in Myanmar

Recruiting

N/A

140

Ministry of Health and Sports, WHO/GMS (World Health Organization/Greater Mekong Subregion)

malaria, Fever

ACTRN12618001999224: Monitoring and evaluation of the efficacy and safety of Artesunate-Mefloquine (ASMQ) and Artesunate-Pyronaridine (ASP) for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Cambodia

Recruiting

N/A

600

National Center for Parasitology, Entomology, and Malaria Control, World Health Organization, U.S. Agency for International Development

Patients with P. falciparum , Patients with P. vivax

ACTRN12615000171516: Pyronaridine-artesunate efficacy for the treatment of uncomplicated falciparum malaria in Cambodia

Active, not recruiting

N/A

145

World Health Organization, National Centre for Parasitology, Entomology and Malaria Control

Patients with plasmodium falciparum infection

Eurartesim (dihydroartemisinin/piperaquine) / Medicines for Malaria Venture, Leadiant Biosci

NCT05980156: Comparing Chemoprevention Drugs for School-based Malaria Control

Completed

646

RoW

Dihydroartemisinin-Piperaquine, DP, D-Artepp, DuoCotecxin, Artekin, Eurartesim, Ridmal, Chloroquine, Aralen, Hydroxychloroquine, Lariago, Sulfadoxine pyrimethamine, SP

University of Maryland, Baltimore, Kamuzu University of Health Sciences, Doris Duke Charitable Foundation

Malaria,Falciparum, Anemia in Children

07/23

SPARTAN, NCT06347471: The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy

Recruiting

120

RoW

Artemether-lumefantrine, Coartem, Dihydroartemisinin-Piperaquine, Eurartesim, Duocotecxin

Infectious Diseases Research Collaboration, Uganda, London School of Hygiene and Tropical Medicine, Radboud University Medical Center

Falciparum; Malaria

12/25

04/26

NCT06083688: Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi

Recruiting

1000

RoW

Dihydroartemisinin-Piperaquine, DP, D-Artepp, DuoCotecxin, Artekin, Eurartesim, Ridmal, Chloroquine, Aralen, Hydroxychloroquine, Lariago, Sulfadoxine-pyrimethamine-amodiaquine, SPAQ, SPAQ-Co

Liverpool School of Tropical Medicine, Kamuzu University of Health Sciences

Malaria,Falciparum, Anemia in Children

07/25

12/25

CuraVivax, NCT03208907: DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil

Completed

419

RoW

CQ coadministered with PQ, Standard treatment with potential synergy, DHA-PQP coadministered with PQ, Experimental treatment with potential synergy, CQ and PQ starting on Day 42, Standard treatment with no potential synergy, DHA-PQP and PQ starting on Day 42, Experimental treatment with no potential synergy

Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Ministry of Health, Brazil, Oswaldo Cruz Foundation

Malaria, Vivax, Therapeutics

07/21

MATAMAL, NCT04844905: Adjunctive Ivermectin Mass Drug Administration for Malaria Control

Recruiting

24000

RoW

Ivermectin, Placebo, Dihydroartemisinin-piperaquine, Eurartesim

London School of Hygiene and Tropical Medicine, Medical Research Council Unit, The Gambia, Ministerio de Saude Publica, Guinee-Bissau, Bandim Health Project, Instituto Nacional de Estudos e Pesquisas, Guinee-Bissau

Malaria,Falciparum, Neglected Tropical Diseases, Strongyloidiasis, Lymphatic Filariasis, Scabies, Hook Worm, Soil Transmitted Helminths

03/23

08/23

ACTRN12610000178044: A Phase I, pharmacokinetic trial, in healthy Asian and Caucasian volunteers for investigating the pharmacokinetic profiles of Eurartesim (trademark) (40 mg Dihydroartemisinin/320 mg Piperaquine Phosphate)

Recruiting

CPR Pharma Services Pty Ltd, Sigma-Tau i.f.r. S.p.A

Anti-Malarial Treatment of uncomplicated plasmodium falciparum malaria

IGHID12334, NCT06870344: IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding

Recruiting

N/A

36000

RoW

Dihydroartemisinin piperaquine, Eurartesim, Dihydroartemisinin piperaquine + Bacillus thuringiensis israelensis, Long-lasting Insecticidal Net, bed nets

University of North Carolina, Chapel Hill, National Institute of Allergy and Infectious Diseases (NIAID), North Carolina State University, Mbarara University of Science and Technology

Malaria Infection, Malaria Falciparum

03/30

SAR441121 / Sanofi, Medicines for Malaria Venture

ACTRN12618001783213: Safety, Tolerability, Pharmacokinetics (including Food Effect) of Single Ascending Doses of SAR441121 in healthy male subjects.

Recruiting

sanofi-aventis australia ptd ltd, sanofi-aventis R&D

Parasitic Diseases - Plasmodium falciparum infection

MMV367 / GSK, Medicines for Malaria Venture

NCT05979207: Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum

Completed

RoW

MMV367, P. falciparum IBSM infection

Medicines for Malaria Venture, GlaxoSmithKline, Southern Star Research Pty Ltd., ICON plc, University of the Sunshine Coast, QIMR Berghofer Medical Research Institute, Queensland Paediatric Infectious Diseases (QPID) laboratory, Swiss BioQuant A.G., Switzerland

Infections, Vector Borne Diseases, Systemic Inflammatory Response Syndrome, Inflammation, Pathologic Processes, Malaria, Malaria,Falciparum, Parasitemia, Parasitic Diseases, Protozoan Infections, Antimalarials, Anti-Infective Agents

10/23

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Krintafel (tafenoquine) / 60° Pharma

ACTRN12622000272796p: Evaluation of weekly tafenoquine antimalarial prophylaxis in Vietnam People’s Army personnel in South Sudan

Not yet recruiting

Australian Defence Force Malaria and Infectious Disease Institute, Australian Defence Force Malaria and Infectious Disease Institute

Malaria

ACTRN12622000272796: Evaluation of weekly tafenoquine antimalarial prophylaxis in Vietnam People’s Army personnel in South Sudan

Withdrawn

Australian Defence Force Malaria and Infectious Disease Institute, Australian Defence Force Malaria and Infectious Disease Institute

Malaria

TQ, NCT05203744: Escalating Monthly Doses of Tafenoquine in Healthy Volunteers

Not yet recruiting

200

RoW

Tafenoquine prophylaxis, TQ

Prophylaxis

12/22

VET, NCT06575647: Vivax Elimination With Tafenoquine () Study

Active, not recruiting

1000

RoW

Tafenoquine

Shoklo Malaria Research Unit, Mahidol Oxford Tropical Medicine Research Unit

Malaria, Malaria, Vivax, Plasmodium Vivax, Plasmodium Vivax Malaria

12/25

ACTQ, NCT05788094: ACT vs CQ With Tafenoquine for P. Vivax Mono-infection

Recruiting

606

RoW

Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose), Chloroquine plus Tafenoquine (450 mg adult dose), Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)

Shoklo Malaria Research Unit, Mahidol Oxford Tropical Medicine Research Unit, University of Oxford

Malaria, Malaria, Vivax, Plasmodium Vivax Malaria

02/26

08/26

TBM, NCT04984759: Tafenoquine and Primaquine in Colostrum and Breast Milk

Withdrawn

RoW

Primaquine, Primaquine GPO®, Tafenoquine, Kodatef

University of Oxford, Mahidol Oxford Tropical Medicine Research Unit

Healthy Lactating Women

06/25

NCT07052162: Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children

Not yet recruiting

RoW

Single dose tafenoquine (10 mg/kg) given with water, TQ, Tafenoquine succinate, Kodatef, Single dose tafenoquine (10 mg/kg) given with fat

Curtin University, Papua New Guinea Institute of Medical Research, The University of Western Australia

Pharmacokinetics of Tafenoquine

12/25

SEADOT, NCT04704999: Southeast Asia Dose Optimization of Tafenoquine

Recruiting

700

RoW

Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg

University of Oxford, PATH

Plasmodium Vivax Malaria

10/27

02/28

EFFORT, NCT04411836: Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine

Completed

960

RoW

Tafenoquine, Primaquine, Primaquine 7 days

Vivax Malaria, Plasmodium Vivax, Malaria, Vivax, Malaria Relapse

09/24

TADORE, NCT06148792: A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria

Recruiting

1090

RoW

Tafenoquine, Primaquine

Vivax Malaria

03/27

Recruiting

300

RoW

Tafenoquine, Primaquine, Chloroquine

GlaxoSmithKline

Malaria, Vivax

07/26

Not yet recruiting

148

Tafenoquine Oral Tablet, KODATEF™, Arakoda, Placebo

60P Australia Pty Ltd

COVID 19 Disease, Mild to Moderate COVID 19 Disease, SARS-CoV-2, Infectious Disease, Severe Acute Respiratory Syndrome Coronavirus 2

04/24

TQ-BA-2024-1, NCT06207370: Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis

Recruiting

Tafenoquine, Placebo

60 Degrees Pharmaceuticals LLC

Babesiosis

03/25

07/25

TQ-BA-2024-3, NCT06656351: Phase 2 Open Label Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

Not yet recruiting

Tafenoquine 100mg

60 Degrees Pharmaceuticals LLC

Chronic Babesiosis

02/27

09/27

ACTRN12620000995976: Blood stage antimalarial activity of tafenoquine in healthy subjects infected with Plasmodium falciparum

Completed

QIMR Berghofer Medical Research Institute, Bill and Melinda Gates Foundation

Malaria

NCT06478641: Expanded Use in Persistent (B. Microti) Babesiosis

Available

N/A

Tafenoquine

60 Degrees Pharmaceuticals LLC

Persistent Babesiosis

Trust, NCT05096702: Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil

Active, not recruiting

N/A

16000

RoW

Tafenoquine, Kozenis, Primaquine

Malaria, Vivax, G6PD Deficiency

08/22

09/23

ARCTIC, NCT05753150: Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand

Completed

N/A

187

RoW

Tafenoquine, Kozenis, Primaquine

Dr. Prayuth Sudathip, Medicines for Malaria Venture

Malaria, Vivax, G6PD Deficiency

08/23

10/23

NCT05361486: Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru

Recruiting

N/A

RoW

Medicines for Malaria Venture, Universidad Peruana Cayetano Heredia, UNITAID, ICON plc

Malaria, Vivax

10/24

CUREMA, NCT05540470: Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield

Recruiting

N/A

5000

RoW

PART, chloroquine, primaquine, tafenoquine, module A, Malakit, module B, CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS, ORPAL 3 - 4, QUALITATIVE STUDY

Centre Hospitalier de Cayenne, Oswaldo Cruz Foundation, Foundation for Scientific Research Suriname (SWOS) Paramaribo, Suriname

Malaria, Vivax

12/24

12/25

cabamiquine (M5717) / EMD Serono

NCT05689047: Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)

Completed

RoW

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Acute Malaria

05/24

NCT05974267: Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

Completed

192

RoW

M5717 60 mg, Pyronaridine, Pyronaridine tetraphosphate, Atovaquone-Proguanil, M5717 200 mg, M5717 660mg

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Malaria Infection

12/24

Pyramax (artesunate/pyronaridine) / Medicines for Malaria Venture, Shin Poong Pharma

ACTRN12622001407785: Efficacy and safety of pyronaridine-artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in Gia Lai province, Viet Nam in 2022.

Not yet recruiting

World Health Organization, World Health Organization, National Malaria control program

Patients infected with plasmodium falciparum.

Not yet recruiting

120

Ministry of Health, World Health Oranization , Ministry of Health

Malaria

Recruiting

World Health Organization, World Health Organization, National Malaria control program

Patients infected Plasmodium falciparum , Patients infected Plasmodium vivax

CHIMIO2, NCT04778813: Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso

Not yet recruiting

1050

RoW

Artemether-lumefantrine, Dihydroartemisinin pyperaquin, Artesunate Pyronaridine

Malaria, Burkina Faso

12/21

06/22

APACT, NCT03726593: Drug Combinations of Atovaquone-Proguanil (AP) With ACT

Recruiting

252

RoW

Artesunate and Pyronaridine, Atovaquone Proguanil and Artesunate Pyronaridine, Atovaquone Proguanil and Artesunate Mefloquine

Armed Forces Research Institute of Medical Sciences, Thailand, National Center for Parasitology, Entomology, and Malaria Control (CNM), Naval Medical Research Unit-2 (NAMRU-2)

Plasmodium Falciparum Malaria (Drug Resistant)

08/22

12/22

MALCOV, NCT04695197: Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso

Completed

143

RoW

Artemether-lumefantrine (AL), Coartem, Pyronaridine-artesunate (PA), Pyramax

Covid-19, Malaria

11/22

02/24

NCT05084911: The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)

Completed

1807

Europe, RoW

Pyramax, Placebo

Shin Poong Pharmaceutical Co. Ltd.

COVID-19

03/23

SAFIRE, NCT06962319: Safety of Antimalarials in the FIRst trimEster

Not yet recruiting

1510

RoW

dihydroartemisinin-piperaquine (DP), Pyronaridine-artesunate (PA), Artemether-lumefantrine

Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)

08/28

08/29

Terminated

2/3

120

Ministry of Health, World Health Organization

Patients with Plasmodium falciparum infection, Patients with Plasmodium vivax infection

PROVIDENCE, NCT04701606: The Safety and Efficacy of Pyronaridine-artesunate (PyramaxÂ® or ArtecomÂ®)in COVID-19 Patients

Recruiting

2/3

402

RoW

ArtecomÂ® (pyronaridine-artesunate), PyramaxÂ® (pyronaridine-artesunate), Placebo

Shin Poong Pharmaceutical Co. Ltd.

Covid19

04/22

NCT05441410: Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults

Not yet recruiting

1/2

Pyronaridine Tetraphosphate, Artesunate Drug Combination, Pyramax, PfSPZ Challenge (NF54), MVA ME-TRAP, ChAd63 ME-TRAP, Sodium chloride (NaCl) 0.9%, Placebo: Saline

University Hospital Tuebingen, Sanaria Inc., University of Oxford

Malaria

06/26

NCT05929157: A Crossover Bioavailability Clinical Trial of Parenteral Pyronaridine and Artesunate

Not yet recruiting

1/2

RoW

artesunate-pyronaridine

Centre de Recherche Médicale de Lambaréné, Institute of Tropical Medicine, University of Tuebingen

Severe Malarial Treatment

12/24

06/25

ACTRN12618001621202: Therapeutic efficacy of pyronaridine-artesunate for Plasmodium vivax in Myanmar

Not yet recruiting

N/A

140

Ministry of Health and Sports, WHO/GMS (World Health Organization/Greater Mekong Subregion)

malaria

ACTRN12618001620213: Therapeutic efficacy studies of pyronaridine-artesunate combination for the treatment of uncomplicated Plasmodium falciparum malaria in Myanmar

Recruiting

N/A

140

Ministry of Health and Sports, WHO/GMS (World Health Organization/Greater Mekong Subregion)

malaria, Fever

Recruiting

N/A

600

National Center for Parasitology, Entomology, and Malaria Control, World Health Organization, U.S. Agency for International Development

Patients with P. falciparum , Patients with P. vivax

ACTRN12615000171516: Pyronaridine-artesunate efficacy for the treatment of uncomplicated falciparum malaria in Cambodia

Active, not recruiting

N/A

145

World Health Organization, National Centre for Parasitology, Entomology and Malaria Control

Patients with plasmodium falciparum infection

Eurartesim (dihydroartemisinin/piperaquine) / Medicines for Malaria Venture, Leadiant Biosci

NCT05980156: Comparing Chemoprevention Drugs for School-based Malaria Control

Completed

646

RoW

Dihydroartemisinin-Piperaquine, DP, D-Artepp, DuoCotecxin, Artekin, Eurartesim, Ridmal, Chloroquine, Aralen, Hydroxychloroquine, Lariago, Sulfadoxine pyrimethamine, SP

University of Maryland, Baltimore, Kamuzu University of Health Sciences, Doris Duke Charitable Foundation

Malaria,Falciparum, Anemia in Children

07/23

SPARTAN, NCT06347471: The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy

Recruiting

120

RoW

Artemether-lumefantrine, Coartem, Dihydroartemisinin-Piperaquine, Eurartesim, Duocotecxin

Infectious Diseases Research Collaboration, Uganda, London School of Hygiene and Tropical Medicine, Radboud University Medical Center

Falciparum; Malaria

12/25

04/26

NCT06083688: Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi

Recruiting

1000

RoW

Dihydroartemisinin-Piperaquine, DP, D-Artepp, DuoCotecxin, Artekin, Eurartesim, Ridmal, Chloroquine, Aralen, Hydroxychloroquine, Lariago, Sulfadoxine-pyrimethamine-amodiaquine, SPAQ, SPAQ-Co

Liverpool School of Tropical Medicine, Kamuzu University of Health Sciences

Malaria,Falciparum, Anemia in Children

07/25

12/25

CuraVivax, NCT03208907: DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil

Completed

419

RoW

Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Ministry of Health, Brazil, Oswaldo Cruz Foundation

Malaria, Vivax, Therapeutics

07/21

MATAMAL, NCT04844905: Adjunctive Ivermectin Mass Drug Administration for Malaria Control

Recruiting

24000

RoW

Ivermectin, Placebo, Dihydroartemisinin-piperaquine, Eurartesim

Malaria,Falciparum, Neglected Tropical Diseases, Strongyloidiasis, Lymphatic Filariasis, Scabies, Hook Worm, Soil Transmitted Helminths

03/23

08/23

Recruiting

CPR Pharma Services Pty Ltd, Sigma-Tau i.f.r. S.p.A

Anti-Malarial Treatment of uncomplicated plasmodium falciparum malaria

IGHID12334, NCT06870344: IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding

Recruiting

N/A

36000

RoW

Dihydroartemisinin piperaquine, Eurartesim, Dihydroartemisinin piperaquine + Bacillus thuringiensis israelensis, Long-lasting Insecticidal Net, bed nets

University of North Carolina, Chapel Hill, National Institute of Allergy and Infectious Diseases (NIAID), North Carolina State University, Mbarara University of Science and Technology

Malaria Infection, Malaria Falciparum

03/30

SAR441121 / Sanofi, Medicines for Malaria Venture

ACTRN12618001783213: Safety, Tolerability, Pharmacokinetics (including Food Effect) of Single Ascending Doses of SAR441121 in healthy male subjects.

Recruiting

sanofi-aventis australia ptd ltd, sanofi-aventis R&D

Parasitic Diseases - Plasmodium falciparum infection

MMV367 / GSK, Medicines for Malaria Venture

NCT05979207: Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum

Completed

RoW

MMV367, P. falciparum IBSM infection

10/23

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites